This is an old revision of this page, as edited by Boghog(talk | contribs) at 12:00, 25 April 2020(consistent citation formatting). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 12:00, 25 April 2020 by Boghog(talk | contribs)(consistent citation formatting)
Bupropion/zonisamide (planned trade name Empatic) is an experimental combination drug combination for the treatment of obesity.[1]
It is being developed by Orexigen Therapeutics. It is currently at phase II testing.[2][3] The combination consists of two prescription medications approved by the U.S. Food and Drug Administration (FDA) for other ailments.[4] When mixed together and tested along with proper diet and moderate exercise, they produced a substantial weight loss effect higher than the group taking a placebo.
Empatic was called Excalia before its name was changed.[5]
^Adan RA (February 2013). "Mechanisms underlying current and future anti-obesity drugs". Trends in Neurosciences. 36 (2): 133–40. doi:10.1016/j.tins.2012.12.001. PMID23312373.
